Correction of previously published press release regarding CTA-filing for Phase I study
The press release published by Initiator Pharma at 03:52 p.m. today, October 19, 2021, “Initiator Pharma files CTA for Phase I study with IP2105 in relation to assessment of pain reducing effects ”, included incorrect information regarding the names of Initiator Pharma’s clinical programs. A corrected version of the press release is as follows. Initiator Pharma files CTA for Phase I study for the IPTN2021 program in relation to assessment of pain reducing effects Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today that it has filed a Clinical Trials Application